Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned for continued success due to its strong customer relationships, diverse product offerings, and focus on technology and expansion. The company has a solid financial foundation with a strong cash position and plans to reduce debt for sustained growth. However, investors should consider industry risks, such as potential changes in healthcare regulations or competition from other distributors, when evaluating Medline's stock.

Bears say

Medline is facing potential headwinds from declining tariff rates and higher costs in 2026E. They may struggle to offset these costs with price increases and there is no indication that they have been taking aggressive price increases to offset headwinds. However, they continue to see strong demand, with no slow-down in revenue growth and new client wins. Additionally, their technology and automation systems are impressive, and they have a significant opportunity for growth in other healthcare settings. Overall, while potential headwinds and risks exist, Medline's scale, diverse product offering, and relationships with customers position them well for long-term growth despite potential short-term challenges.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.